Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension

British Journal of Pharmacology

Volumn 173, Issue 9, 2016, Pages 1541-1555

  Avendano M S ^a   Martinez Revelles S ^a   Aguado, A ^a   Simoes M R ^a,b   Gonzalez Amor M ^a   Palacios, R ^a   Guillem Llobat, P ^c   Vassallo, D V ^b   Vila, L ^d   Garcia Puig J ^e   Beltran L M ^e   Alonso, M J ^f   Cachofeiro, M V ^g   Salaices, M ^a,h   Briones, A M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f UNIVERSIDAD REY JUAN CARLOS   (Spain)

^g UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^h UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 2 (8 CHLORO 10,11 DIHYDRODIBENZ[B,F][1,4]OXAZEPINE 10 CARBONYL)HYDRAZINE; ANGIOTENSIN II; CELECOXIB; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2; ELASTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E2; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA; CYCLOOXYGENASE 2 INHIBITOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL STIFFNESS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERTENSION; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE CELL; VASOCONSTRICTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; SPONTANEOUSLY HYPERTENSIVE RAT; STRUCTURE ACTIVITY RELATION; WISTAR RAT;

ANIMALS; CELECOXIB; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIBENZ(B,F)(1,4)OXAZEPINE-10(11H)-CARBOXYLIC ACID, 8-CHLORO-, 2-ACETYLHYDRAZIDE; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; MALE; MICE; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR STIFFNESS;

EID: 84961839562     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13457     Document Type: Article

References (55)

1. Aguado A, Galán M, Zhenyukh O, Wiggers GA, Roque FR, Redondo S, et al., (2013). Mercury induces proliferation and reduces cell size in vascular smooth muscle cells through MAPK, oxidative stress and cyclooxygenase-2 pathways. Toxicol Appl Pharmacol 268: 188-200.
2. Aguado A, Rodríguez C, Martínez-Revelles S, Avendaño MS, Zhenyukh O, Orriols M, et al., (2015). HuR mediates the synergistic effects of angiotensin II and IL-1β on vascular COX-2 expression and cell migration. Br J Pharmacol 172: 3028-3042.
3. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015a). The Concise Guide to PHARMACOLOGY 2015/16: G Protein-Coupled Receptors. Br J Pharmacol 172: 5744-5869.
4. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
5. Álvarez Y, Pérez-Girón JV, Hernanz R, Briones AM, García-Redondo A, Beltrán A, et al., (2007). Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats. J Pharmacol Exp Ther 321: 381-388.
6. Amer M, Bead VR, Bathon J, Blumenthal RS, Edwards DN, (2010). Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol Rev 18: 204-212.
7. Beltrán AE, Briones AM, García-Redondo AB, Rodríguez C, Miguel M, Alvarez Y, et al., (2009). p38 MAPK contributes to angiotensin II-induced COX-2 expression in aortic fibroblasts from normotensive and hypertensive rats. J Hypertens 27: 142-154.
8. Briones AM, Arribas SM, Salaices M, (2010). Role of extracellular matrix in vascular remodeling of hypertension. Curr Opin Nephrol Hypertens 19: 187-194.
9. Briones AM, González JM, Somoza B, Giraldo J, Daly CJ, Vila E, et al., (2003). Role of elastin in spontaneously hypertensive rat small mesenteric artery remodelling. J Physiol 552: 185-195.
10. Briones AM, Rodríguez-Criado N, Hernanz R, García-Redondo AB, Rodrigues-Díez RR, Alonso MJ, et al., (2009). Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 54: 142-149.
11. Bush E, Maeda N, Kuziel WA, Dawson TC, Wilcox JN, DeLeon H, et al., (2000). CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension 36: 360-363.
12. Buus NH, Mathiassen ON, Fenger-Grøn M, Præstholm MN, Sihm I, Thybo NK, et al., (2013). Small artery structure during antihypertensive therapy is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 31: 791-797.
13. Camacho M, Dilmé J, Solà-Villà D, Rodríguez C, Bellmunt S, Siguero L, et al., (2013). Microvascular COX-2/mPGES-1/EP-4 axis in human abdominal aortic aneurysm. J Lipid Res 54: 3506-3515.
14. Chen L, Miao Y, Zhang Y, Dou D, Liu L, Tian X, et al., (2012). Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility. Arterioscler Thromb Vasc Biol 32: 3024-3032.
15. Chen L, Yang G, Xu X, Grant G, Lawson JA, Bohlooly-Y M, et al., (2013). Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1. Circulation 127: 233-243.
16. Chen L, Yang G, Monslow J, Todd L, Cormode DP, Tang J, et al., (2014). Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice. Proc Natl Acad Sci U S A 111: 6828-6833.
17. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA, (2006). Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116: 1391-1399.
18. Cipollone F, Cicolini G, Bucci M, (2008). Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 118: 161-180.
19. Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M, et al., (2004). Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 109: 1482-1488.
20. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPH, Giembycz MA, et al., (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461-3471.
21. de Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL, (2005). Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 25: 2106-2113.
22. Félétou M, Huang Y, Vanhoutte PM, (2011). Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 164: 894-912.
23. Foudi N, Gomez I, Benyahia C, Longrois D, Norel X, (2012). Prostaglandin E2 receptor subtypes in human blood and vascular cells. Eur J Pharmacol 695: 1-6.
24. Francois H, Athirakul K, Mao L, Rockman H, Coffman TM, (2004). Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension 43: 364-369.
25. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD, (2007). Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 73: 227-236.
26. Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, et al., (2007). Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest 117: 2496-2505.
27. Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M, Nakatani Y, Oh-Ishi S, et al., (2004). Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. J Biol Chem 279: 33684-33695.
28. Kane MO, Etienne-Selloum N, Madeira SV, Sarr M, Walter A, Dal-Ros S, et al., (2010). Endothelium-derived contracting factors mediate the AngII-induced endothelial dysfunction in the rat aorta: preventive effect of red wine polyphenols. Pflugers Arch 459: 671-679.
29. Kellogg AP, Converso K, Wiggin T, Stevens M, Pop-Busui R, (2009). Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am J Physiol Heart Circ Physiol 296: H453-H461.
30. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
31. King VL, Trivedi DB, Gitlin JM, Loftin CD, (2006). Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 26: 1137-1143.
32. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP, (2004). Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 286: H1416-H1424.
33. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al., (2013). 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34: 2159-2219.
34. McGrath JC, Lilley E, (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189-3193.
35. Martínez-Revelles S, Avendaño MS, García-Redondo AB, Alvarez Y, Aguado A, Pérez-Girón JV, et al., (2013). Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal 18: 51-65.
36. Mohamed R, Jayakumar C, Ramesh G, (2013). Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6. Lab Invest 93: 933-945.
37. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SPH, Buneman OP, et al., NC-IUPHAR(2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
38. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al., (2001). Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104: 191-196.
39. Rizzoni D, Porteri E, Boari GE, de Ciuceis C, Sleiman I, Muiesan ML, et al., (2003). Prognostic significance of small-artery structure in hypertension. Circulation 108: 2230-2235.
40. Safar ME, Nilsson PM, Blacher J, Mimran A, (2012). Pulse pressure, arterial stiffness, and end-organ damage. Curr Hypertens Rep 14: 339-344.
41. Schiffrin EL, (2012). Vascular remodeling in hypertension: mechanisms and treatment. Hypertension 59: 367-374.
42. Sparks MA, Makhanova NA, Griffiths RC, Snouwaert JN, Koller BH, Coffman TM, (2013). Thromboxane receptors in smooth muscle promote hypertension, vascular remodeling, and sudden death. Hypertension 61: 166-173.
43. Tian XY, Wong WT, Leung FP, Zhang Y, Wang YX, Lee HK, et al., (2012). Oxidative stress-dependent cyclooxygenase-2-derived prostaglandin f(2α) impairs endothelial function in renovascular hypertensive rats. Antioxid Redox Signal 16: 363-373.
44. Ungrin MD, Carrière MC, Denis D, Lamontagne S, Sawyer N, Stocco R, et al., (2001). Key structural features of prostaglandin E(2) and prostanoid analogs involved in binding and activation of the human EP(1) prostanoid receptor. Mol Pharmacol 59: 1446-1456.
45. Virdis A, Bacca A, Colucci R, Duranti E, Fornai M, Materazzi G, et al., (2013). Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. Hypertension 62: 337-344.
46. Virdis A, Colucci R, Neves MF, Rugani I, Aydinoglu F, Fornai M, et al., (2012). Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. Eur Heart J 33: 2225-2234.
47. Virdis A, Colucci R, Versari D, Ghisu N, Fornai M, Antonioli L, et al., (2009). Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. Hypertension 53: 1008-1016.
48. Wang M, Ihida-Stansbury K, Kothapalli D, Tamby MC, Yu Z, Chen L, et al., (2011). Microsomal prostaglandin E2 synthase-1 modulates the response to vascular injury. Circulation 123: 631-639.
49. Wang M, Lee E, Song W, Ricciotti E, Rader DJ, Lawson JA, et al., (2008). Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117: 1302-1309.
50. Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S, et al., (2011). Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 124: 1370-1381.
51. Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, et al., (2003). Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42: 310-315.
52. Wong SL, Lau CW, Wong WT, Xu A, Au CL, Ng CF, et al., (2011). Pivotal role of protein kinase Cdelta in angiotensin II-induced endothelial cyclooxygenase-2 expression: a link to vascular inflammation. Arterioscler Thromb Vasc Biol 31: 1169-1176.
53. Wu J, Thabet SR, Kirabo A, Trott DW, Saleh MA, Xiao L, et al., (2014). Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circ Res 114: 616-625.
54. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW, et al., (2004). Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110: 301-308.
55. Zhang J, Zou F, Tang J, Zhang Q, Gong Y, Wang Q, et al., (2013). Cyclooxygenase-2-derived prostaglandin E2 promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res 113: 104-114.